Resolving disease
and promoting
host defense
Pioneering
Thetis is a clinical-stage pharmaceutical company developing TP-317, a BLT1 agonist, as an oral therapy for inflammatory bowel disease (IBD) and solid tumor cancers.
TP-317
TP-317 is a first-in-class Resolvin E1 (RvE1) drug candidate that engages the LTB4-BLT1 pathway to mobilize the body’s natural healing ability.
HEALER™
Our innovative technology is a fundamental breakthrough enabling the development of Resolvin E1 therapeutics.